{"id":726201,"title":"Use of live attenuated influenza vaccine (LAIV) in HIV-infected individuals: Summary of NACI systematic review and recommendation, CCDR 46(9) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-02-05","captureTimestamp":"2026-02-05T17:23:44.600000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-9-september-3-2020/national-advisory-committee-immunization-laiv-hiv-infected-individuals.html","snippet":"NACI recommendations on the use of LAIV and HIV-infected individuals Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 46–9: Force Health Protection Date published: September 3, 2020 ISSN: 1481-8531 Subscribe to CCDR Submit your…","rawSnapshotUrl":"/api/snapshots/raw/726201","browseUrl":"https://replay.healtharchive.ca/job-7/20260205172344/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-9-september-3-2020/national-advisory-committee-immunization-laiv-hiv-infected-individuals.html#ha_snapshot=726201","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}